SAMANTHA MARSEE: Open Payments
NPI 1972240588 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$816 in 38 payments from 13 companies in 2025. Trend: 2023 $948 · 2024 $958 · 2025 $816
Food & beverage: $816
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $163 |
| AstraZeneca Pharmaceuticals LP | 8 | $152 |
| Exact Sciences Corporation | 4 | $78 |
| Lilly USA, LLC | 4 | $77 |
| PFIZER INC. | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| ABBVIE INC. | 2 | $44 |
| Amgen Inc. | 2 | $37 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
Products named: Wegovy, The Cologuard Plus Collection Kit, MOUNJARO, AIRSUPRA, ZORYVE, NEXLETOL, Rybelsus, FARXIGA.
Industry payments across MD — which companies pay providers there.
